<DOC>
	<DOCNO>NCT00058253</DOCNO>
	<brief_summary>This phase I trial study side effect best dose combination chemotherapy treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , docetaxel 17-N-allylamino-17-demethoxygeldanamycin , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) administer docetaxel patient progressive metastatic prostate cancer progressive metastatic unresectable solid tumor . II . Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) . Patients assign 1 2 treatment group . Group 1 : Patients receive docetaxel IV 1 hour 17-AAG IV 1-2 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Group 2 : Patients receive docetaxel IV 30 minute 17-AAG group 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient per group receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 20 additional patient ( 10 per group ) treat MTD . Patients follow every 2-3 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm metastatic unresectable malignancy standard curative palliative therapy exist longer effective Progressive disease manifest follow parameter For prostate cancer : Must castrate , metastatic disease define disease progression surgical castration treatment gonadotropinreleasing hormone ( GnRH ) analog ( testosterone level less 50 ng/mL ) Patients undergone surgical orchiectomy continue medical therapy maintain castrate level testosterone Progressive metastatic disease image study ( bone scan , CT scan , MRI ) OR metastatic disease rise prostatespecific antigen ( PSA ) Biochemical progression indicate least 3 rise PSA value ( obtain least 1 week apart ) baseline OR 2 rise PSA value ( 1 month apart ) , percentage increase range value least 25 % Patients receive antiandrogen part firstline hormonal therapy must show progression disease antiandrogen prior study enrollment For solid tumor : Development new lesion increase preexist lesion bone scintigraphy , CT scan , MRI , positron emission tomography , physical examination Patients whose sole criterion progression increase biochemical marker ( e.g. , carcinoembryonic antigen CA 153 ) increase symptom eligible Patients metastatic disease must progress extent require palliative treatment within 4 week study entry No active brain metastasis Performance status Karnofsky 70100 % More 6 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 1.5 time ULN PT ≤ 1.1 time ULN Creatinine great 1.4 mg/dL within ULN Creatinine clearance great 55 mL/min No prior history pulmonary toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine ) No dyspnea ≥ grade 2 rest room air No requirement supplementary oxygen therapy oxygen saturation ≤ 88 % No clinically significant pulmonary comorbidities require medication ( e.g. , severe chronic obstructive pulmonary disease could predispose patient pulmonary toxicity ) QTc ≤ 450 msec male patient ( 470 female patient ) LVEF &gt; 40 % echocardiogram MUGA Echocardiogram MUGA require patient follow : Myocardial infarction &gt; 1 year ago NYHA class I II CHF Atrial fibrillation Right leave bundle branch block EKG No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No myocardial infarction within past year No active ischemic heart disease within past year No New York Heart Association ( NYHA ) class III IV congestive heart failure ( CHF ) No poorly control angina No uncontrolled dysrhythmia No congenital long QT syndrome No leave bundle branch block No significant cardiac disease No prior history cardiac toxicity receive anthracyclines doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history severe hypersensitivity reaction paclitaxel , docetaxel , polysorbate 80 No ongoing active infection No psychiatric illness social situation would preclude study compliance No grade 2 great symptomatic peripheral neuropathy No allergy egg egg product No concurrent uncontrolled illness At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy sole measurable lesion No prior mantlefield radiotherapy See Disease Characteristics No concurrent surgery sole measurable lesion Recovered prior therapy At least 1 week since prior ketoconazole recover At least 4 week since prior investigational anticancer therapeutic drug No concurrent combination antiretroviral therapy HIVpositive patient No concurrent medication prolong QTc interval No concurrent medication use control arrhythmias Calcium blocker beta blocker allow No concurrent investigational agent No concurrent anticancer agent therapy ( investigational commercial ) No concurrent CYP3A4 inhibitor , include follow : Fluconazole Itraconazole Ketoconazole Macrolide antibiotic ( azithromycin , clarithromycin , erythromycin , troleandomycin ) Nifedipine Verapamil Diltiazem Cyclosporine Grapefruit juice No concurrent CYP3A4 inducer , include follow : Carbamazepine Phenobarbital Phenytoin Rifampin No concurrent herbal extract tincture CYP3A4 inhibitory activity , include follow : Hydrastis canadensis ( goldenseal ) Hypericum perforatum ( St. John 's wort ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Matricaria chamomilla ( chamomile ) Glycyrrhiza glabra ( licorice ) Dillapiol Hypericin Naringenin Concurrent CYP3A4 substrates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>